United KingdomA new urine test called the Galeas test has shown promise in detecting over 92% of bladder cancer cases, according to an NHS trial. The test identifies genetic material shed into urine by bladder cancer and was developed by the University of Birmingham with support from Cancer Research UK (CRUK). While it is not intended to replace traditional diagnostic methods like cystoscopies, it could help prioritize patients for urgent testing based on their risk level. The test detects over 450 DNA mutations linked to bladder cancer across 23 genes. A negative result indicates a more than 99% likelihood that the patient does not have bladder cancer. The test has been commercialized by Nonacus under a licensing agreement with the university and CRUK, which receive a portion of the revenue. Researchers emphasize the need for further study but highlight the potential benefits of a faster, less invasive diagnostic method.
Bias read (Center): The article presents findings from a medical study and quotes researchers and organizations involved in the development of the test. There is no indication of ideological framing or bias in the presentation of the information. The content focuses on scientific progress and healthcare improvements, a
